Speaker illustration

Doctor Boglarka Veres

Semmelweis University, Budapest (Hungary)

Member of:

European Heart Rythm Association

Boglárka Veres was born in Hungary in 1996. She acquired her medical degree in 2020 at Semmelweis University Faculty of Medicine. During her undergraduate years, she was conducting student research from 2017 to 2020 at Semmelweis University Heart and Vascular Center. Her research field focused on heart failure and cardiac resynchronization therapy. She presented her results at scientific conferences and won second place at the Semmelweis University Student’s Scientific Association’s TDK conference in 2019. Therefore she qualified to attend the National Student’s Scientific Association’s TDK conference in 2019, and she won second place. She wrote her thesis about „Machine learning defined predictors of mortality in ischemic and nonischemic heart failure patients undergoing CRTP or CRTD implantation”, and she received the first prize at Rector's Competition. In 2020 she received a scholarship and started her postgraduate studies at Semmelweis University Doctoral School.

The benefits of adding a defibrillator to cardiac resynchronization therapy - systematic review and meta-analysis

Event: Heart Failure 2022

Topic: Cardiac Resynchronisation Therapy (CRT)

Session: Unraveling epidemiology in heart failure

Thumbnail

The benefits of adding a defibrillator to cardiac resynchronization therapy - Systematic review and meta-analysis

Event: EHRA 2022

Topic: Cardiac Resynchronisation Therapy (CRT)

Session: Moderated ePosters - More on pacing

Thumbnail

Long-term outcome after adding an ICD to CRT in non-ischemic patients

Event: ESC Congress 2021 - The Digital Experience

Topic: Device Treatment

Session: Ventricular arrhythmias and sudden cardiac death e-posters

Thumbnail

Long-term mortality benefit of adding an ICD to CRT in non-ischemic patients

Event: EHRA 2021

Topic: Cardiac Resynchronisation Therapy (CRT)

Session: New insights into ICD therapy

Thumbnail

This platform is supported by

logo Novo Nordisk